Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders
- Written by PR Newswire
SHANGHAI and OAKLAND, Calif., Sept. 17, 2025 /PRNewswire/ -- Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio today announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target siRNA candidate for lipid management in patients with...













